Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

Author(s):

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Melody Chang, RPh, MBA, BCOP

Experts discuss how they balance safety, efficacy, and overall patient prognosis when selecting third-line treatments for metastatic colorectal cancer (mCRC) and explore how the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, informing treatment decisions.

EP: 1.Third-Line Treatment Options in mCRC: A Clinical Overview

Now Viewing

EP: 2.Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

Video content above is prompted by the following:

When selecting third-line treatments for mCRC, how do you balance safety, efficacy, and overall patient prognosis?
How do the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, and how can these differences inform treatment decisions?